Multicenter , Open-Label , Prospective Evaluation of the Conversion from Previous Opioid Analgesics to Extended-Release Hydromorphone Hydrochloride Administered Every 24 Hours to Patients with Persistent Moderate to Severe Pain

@inproceedings{Bearden2006MulticenterO,
  title={Multicenter , Open-Label , Prospective Evaluation of the Conversion from Previous Opioid Analgesics to Extended-Release Hydromorphone Hydrochloride Administered Every 24 Hours to Patients with Persistent Moderate to Severe Pain},
  author={James Dewitt Bearden and Jacques R. Caldwell and Marilyn K. Croghan},
  year={2006}
}
Background: Hydromorphone hydrochloride is a p-opioid agonist with dose-dependent analgesic properties. Extended-release hydromorphone hydrochloride (ER hydromorphone HC1) capsules have been developed for administration every 24 hours. Objectives: This prospective evaluation focused on the first (ie, conversion) phase of 2 identically designed, randomized… CONTINUE READING